Skip to search formSkip to main contentSkip to account menu

CYT997

Known as: Tubulin Inhibitor CYT997 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

LexibulinPyridinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CYT997 through enhancing excessively high reactive oxygen species-induced apoptosis
The functional relationship between apoptosis and autophagy in anticancer drug treatment is extremely complex, and the molecular… 
2013
2013
The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins
The orally active microtubule-depolymerizing agent CYT997 is potently cytotoxic to a variety of tumors in vitro and in vivo… 
2011
2011
The Microtubule Depolymerizing Agent CYT997 Causes Extensive Ablation of Tumor Vasculature In Vivo
The orally active microtubule-disrupting agent (S)-1-ethyl-3-(2-methoxy-4-(5-methyl-4-((1-(pyridin-3-yl)butyl)amino)pyrimidin-2… 
2011
2011
CYT997 Causes apoptosis in human multiple myeloma
SummaryMultiple Myeloma (MM) is an incurable malignancy of mature plasma cells. Microtubule targeting agents (MTAs) are an… 
2010
2010
Carboplatin combined with the vascular-disrupting agent CYT997 for recurrent glioblastoma multiforme.
e13591 Background: The outcome in recurrent glioblastoma multiforme (GBM) remains poor although recent experience with regimens… 
2009
2009
Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer.
3568 Background: CYT997 is a novel, small-molecule vascular disrupting agent which binds tubulin and inhibits microtubule… 
2009
2009
Discovery of CYT997: a structurally novel orally active microtubule targeting agent.
2009
2009
CYT 997 : a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
CYT997 is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule… 
2008
2008
Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer
3504 Background: CYT997 binds α-tubulin, inhibits microtubule assembly and demonstrates potent anti-tumour and vascular… 
2007
2007
Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)